-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Benzinga·05/14/2025 15:07:44
Listen to the news
Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $9 to $5.